FDA Approves New Medication for Plaque Psoriasis


FDA Approves New Medication for Plaque Psoriasis

 

On January 1, 2015, the United States Food & Drug Administration approved Cosentyx (secukinumab) for use in moderate to severe plaque psoriasis.

Cosentyx is the first injectable medication approved for psoriasis which targets IL-17A, a molecule responsible for psoriatic inflammation.

The safety and efficacy of Cosentyx were determined in two large phase 3 trials involving over 2,000 participants. Both studies showed that after 12 weeks of therapy with Cosentyx, approximately 80% of patients had 75% improvement in their psoriasis and about one quarter of patients were completely free of psoriasis. Rates of infection were higher with Cosentyx than with placebo but were similar to those of Enbrel.

Similar to almost all other injectable psoriasis medications, Cosentyx is injected directly under the skin and is intended for use in psoriasis patients who are candidates for systemic therapy.

Earlier this month, the European Commission also approved Cosentyx as a first-line systemic treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.